MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B	zanubrutinib Sensitive: B - Late Trials zanubrutinib Sensitive : B
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	ibrutinib Sensitive: C2 – Inclusion Criteria ibrutinib Sensitive : C2	ibrutinib Sensitive: C2 – Inclusion Criteria ibrutinib Sensitive : C2
MYD88 mutation	Lymphoma	MYD88 mutation	Lymphoma	ibrutinib Sensitive: C2 – Inclusion Criteria ibrutinib Sensitive : C2	ibrutinib Sensitive: C2 – Inclusion Criteria ibrutinib Sensitive : C2
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	orelabrutinib Sensitive: C2 – Inclusion Criteria orelabrutinib Sensitive : C2	orelabrutinib Sensitive: C2 – Inclusion Criteria orelabrutinib Sensitive : C2
MYD88 mutation	Marginal Zone Lymphoma	MYD88 mutation	Marginal Zone Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3	methotrexate Sensitive: C3 – Early Trials methotrexate Sensitive : C3
MYD88 mutation	Marginal Zone Lymphoma	MYD88 mutation	Marginal Zone Lymphoma	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3	zanubrutinib Sensitive: C3 – Early Trials zanubrutinib Sensitive : C3
MYD88 mutation	Lymphoma	MYD88 mutation	Lymphoma	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3	rituximab + orelabrutinib Sensitive: C3 – Early Trials rituximab + orelabrutinib Sensitive : C3
MYD88 mutation	Lymphoma	MYD88 mutation	Lymphoma	rituximab + lenalidomide + acalabrutinib Sensitive: C3 – Early Trials rituximab + lenalidomide + acalabrutinib Sensitive : C3	rituximab + lenalidomide + acalabrutinib Sensitive: C3 – Early Trials rituximab + lenalidomide + acalabrutinib Sensitive : C3
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	BTK inhibitor Sensitive: C3 – Early Trials BTK inhibitor Sensitive : C3	BTK inhibitor Sensitive: C3 – Early Trials BTK inhibitor Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3	pomalidomide Sensitive: C3 – Early Trials pomalidomide Sensitive : C3
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3	inotuzumab ozogamicin Sensitive: C3 – Early Trials inotuzumab ozogamicin Sensitive : C3
MYD88 mutation	Waldenstrom Macroglobulinemia	MYD88 mutation	Waldenstrom Macroglobulinemia	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4	rituximab Sensitive: C4 – Case Studies rituximab Sensitive : C4
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D	BTK inhibitor + KT-413 Sensitive: D – Preclinical BTK inhibitor + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D	rituximab + KT-413 Sensitive: D – Preclinical rituximab + KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D	KT-413 Sensitive: D – Preclinical KT-413 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	BTM-3566 Sensitive: D – Preclinical BTM-3566 Sensitive : D	BTM-3566 Sensitive: D – Preclinical BTM-3566 Sensitive : D
MYD88 mutation	Diffuse Large B Cell Lymphoma	MYD88 mutation	Diffuse Large B Cell Lymphoma	pacritinib Sensitive: D – Preclinical pacritinib Sensitive : D	pacritinib Sensitive: D – Preclinical pacritinib Sensitive : D

MYD88 mutation

Associations